Forbes: Finch CEO Mark Smith Named to 30 Under 30

Article Excerpt: "Smith's company, OpenBiome, developed a therapy called fecal microbiota transplantation to treat Clostridium difficile, a common hospital-acquired infection. Like a blood bank for human stool, the nonprofit's work has helped over 18,000 patients. Smith's other company, Finch Therapeutics, compliments OpenBiome in that it is designing products comprised of pure cultures of microbes that will serve the same purposes of fecal microbiotas transplantation while also being safer and more scalable."